Novo Nordisk, the Danish pharmaceutical company known for Ozempic, is suspending new hires as it struggles to meet its lofty sales expectations. The move highlights the broader financial pressures the company has faced in recent months.

Merck’s stock encounters significant hurdles as it approaches the Keytruda patent cliff and grapples with challenges related to Gardasil. A recent SWOT analysis reveals potential vulnerabilities that could impact the pharmaceutical giant’s financial outlook.

Macquarie has downgraded Dr. Reddy’s Laboratories to a Neutral rating due to concerns over gRevlimid. This shift signals potential challenges ahead for the pharmaceutical company and could influence investor decisions.

Merck & Co., Inc. is projected to achieve an earnings per share of $9.62 in fiscal year 2026, according to new estimates released by Cantor Fitzgerald analyst C. Gould. The research note was issued to investors on June 9th.

In a decisive move to reduce prescription drug costs, President Donald Trump has signed an executive order giving pharmaceutical companies 30 days to voluntarily lower prices or face future limits on government payments.

In a bid to tackle soaring medication costs, President Donald Trump announced he will sign an executive order intended to reduce prices, resurrecting a previously unsuccessful initiative.

Duchesnay Pharmaceutical Group has established an Advisory Board comprising five external experts. This strategic move aims to leverage their diverse experience to guide the company’s continued growth and success.

Aspen Pharmacare Holdings saw its share price reach a new 52-week low of $8.26 on Tuesday, marking a significant downturn for the global pharmaceutical manufacturer. The sharp decline raises questions about the company’s financial trajectory amid shifting market dynamics.